Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial
In this medfyle
STAPRA inconclusive due to low trial recruitment.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the RMD Open, EULAR’s official journal, through an official agreement with BMJ.
The summary content was prepared by Marie Farrow for Medfyle, reviewed & approved by Alain Saraux, MD, PhD, University and CHU Brest, Brest, France.
Original article:
van Boheemen L, Turk S, Beers-Tas MV, et al. Atorvastatin is unlikely to prevent rheumatoid arthritis in high risk individuals: results from the prematurely stopped STAtins to Prevent Rheumatoid Arthritis (STAPRA) trial. RMD Open 2021;7:e001591. doi: 10.1136/rmdopen-2021-001591
The authors of the original article had no part in the creation of the summary.
Copyright © 2020 BMJ Publishing Group Limited and Globalport (International) Limited. All rights reserved.
The summaries, expert commentaries and slides included in this Medfyle are co-owned by BMJ and GlobalPort (International) Limited. The original journal article is an exclusive copyright of BMJ Publishing Group Limited.
